Autopsy report · NCT00784836

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

“Terminated early by Sponsor for business reasons unrelated to safety.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 5 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Biogen

Sponsor type

Industry

Conditions

Multiple Sclerosis

Interventions

BG9418 (interferon beta 1-a)

Participants

3

Sites

2

Countries

United States

Trials that died the same way

• LifeNet: Extracellular Matrix Graft in Rotator Cuff Repair
  “Sponsor terminated early” (78% match in meaning)
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
  “Terminated by sponsor” (77% match in meaning)
• Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
  “Sponsor's discretion to termination due to business decision.” (76% match in meaning)
• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
  “Terminated due to the sponsor's decision.” (75% match in meaning)
• Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
  “Terminated by previous Sponsor decision” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.